PET scans as a predictive marker of survival in advanced colorectal cancer

Clinical Colorectal Cancer

Volumn 14, Issue 1, 2015, Pages 35-40

  Choi, Minsig ^a   Kollepara, Sri Lakshmi S ^b   Heilbrun, Lance K ^c   Smith, Daryn ^c   Shields, Anthony F ^c   Philip, Philip A ^c  

^a STONY BROOK UNIVERSITY   (United States)

^b PROVIDENCE HOSPITAL   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Metabolic response; Metastatic colorectal cancer; Prognostic marker; Systemic chemotherapy; Treatment response

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUORODEOXYGLUCOSE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; COLORECTAL CANCER; CORRELATION ANALYSIS; FEMALE; FOLLOW UP; HUMAN; MALE; METASTASIS; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; RADIOLOGICAL PARAMETERS; RETROSPECTIVE STUDY; STANDARDIZED UPTAKE VALUE; STATISTICAL SIGNIFICANCE; TIME TO PROGRESSION; TREATMENT RESPONSE; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY; PROCEDURES; SURVIVAL RATE; TREATMENT OUTCOME; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84922594347     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2014.10.001     Document Type: Article

References (26)

1. R. Siegel, C. Desantis, and A. Jemal Colorectal cancer statistics, 2014 CA Cancer J Clin 64 2014 104 117
2. A. Venook, D. Niedzwieki, and H. Lenz CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC) (abstract LBA3) J Clin Oncol 32 2014 5s
3. L.B. Saltz, S. Clarke, and E. Diaz-Rubio Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study J Clin Oncol 26 2008 2013 2019
4. S. Kopetz, G.J. Chang, and M.J. Overman Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy J Clin Oncol 27 2009 3677 3683
5. J.R. Anderson, K.C. Cain, and R.D. Gelber Analysis of survival by tumor response J Clin Oncol 1 1983 710 719
6. D. Delbeke, and W.H. Martin FDG PET and PET/CT for colorectal cancer Methods Mol Biol 727 2011 77 103
7. E.K. Pauwels, V.R. McCready, and J.H. Stoot The mechanism of accumulation of tumour-localising radiopharmaceuticals Eur J Nucl Med 25 1998 277 305
8. P. Flamen, O.S. Hoekstra, and F. Homans Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography (PET) Eur J Cancer 37 2001 862 869
9. L.F. de Geus-Oei, B. Wiering, and P.F. Krabbe FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma Ann Oncol 17 2006 1650 1655
10. H. Young, R. Baum, and U. Cremerius Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group Eur J Cancer 35 1999 1773 1782
11. R.L. Wahl, H. Jacene, and Y. Kasamon From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors J Nucl Med 50 suppl 1 2009 122S 150S
12. E.T. Lee, and J.W. Wang Statistical Methods for Survival Data Analysis. Wiley Series in Probability and Statistics 3rd edition 2003 John Wiley & Sons New York
13. P. Therasse, S.G. Arbuck, and E.A. Eisenhauer New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
14. H. Schoder, A. Noy, and M. Gonen Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin lymphoma J Clin Oncol 23 2005 4643 4651
15. P. Flamen, A. Lerut, and E. Van Cutsem Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma J Clin Oncol 18 2000 3202 3210
16. H. Kato, T. Miyazaki, and M. Nakajima The incremental effect of positron emission tomography on diagnostic accuracy in the initial staging of esophageal carcinoma Cancer 103 2005 148 156
17. A. Dimitrakopoulou-Strauss, L.G. Strauss, and J. Rudi PET-FDG as predictor of therapy response in patients with colorectal carcinoma Q J Nucl Med 47 2003 8 13
18. M. Findlay, H. Young, and D. Cunningham Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil J Clin Oncol 14 1996 700 708
19. S. De Bruyne, N. Van Damme, and P. Smeets Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases Br J Cancer 106 2012 1926 1933
20. P. Bystrom, A. Berglund, and U. Garske Early prediction of response to first-line chemotherapy by sequential [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with advanced colorectal cancer Ann Oncol 20 2009 1057 1061
21. L.F. de Geus-Oei, H.W. van Laarhoven, and E.P. Visser Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer Ann Oncol 19 2008 348 352
22. E. Van Cutsem, C.H. Kohne, and E. Hitre Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
23. V. Kalff, C. Duong, and E.G. Drummond Findings on 18F-FDG PET scans after neoadjuvant chemoradiation provides prognostic stratification in patients with locally advanced rectal carcinoma subsequently treated by radical surgery J Nucl Med 47 2006 14 22
24. M.C. Tan, D.C. Linehan, and W.G. Hawkins Chemotherapy-induced normalization of FDG uptake by colorectal liver metastases does not usually indicate complete pathologic response J Gastrointest Surg 11 2007 1112 1119
25. J.A. Maisonobe, C.A. Garcia, and H. Necib Comparison of PET metabolic indices for the early assessment of tumour response in metastatic colorectal cancer patients treated by polychemotherapy Eur J Nucl Med Mol Imaging 40 2013 166 174
26. I. Buvat, H. Necib, and C. Garcia Lesion-based detection of early chemosensitivity using serial static FDG PET/CT in metastatic colorectal cancer Eur J Nucl Med Mol Imaging 39 2012 1628 1634